A carregar...
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database
OBJECTIVE: Anti–tumor necrosis factor (anti‐TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti‐TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated,...
Na minha lista:
| Publicado no: | Arthritis Rheumatol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6174965/ https://ncbi.nlm.nih.gov/pubmed/29623679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40508 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|